Agnes K Kiragga

Optimising community pharmacy PrEP delivery for cisgender female sex workers in Uganda: Protocol for a mixed-methods study

Ivan Segawa, Katrina F. Ortblad, Herbert Kadama, Diana Natukunda et autres

INTRODUCTION: Pre-exposure prophylaxis (PrEP) use among cisgender female sex workers (FSWs), a population at disproportionately high HIV acquisition risk in Uganda, remains suboptimal. Uptake and continued use are constrained by barriers, such as limited clinical hours, long distances to access facility-based PrEP …

Ouganda, us, Kenya (code pays fourni par la source)

Feasibility and Preliminary Effectiveness of a Discrete Choice-Based Pre-Exposure Prophylaxis Delivery Model for Female Sex Workers in Uganda

Ruth Mpirirwe, Andrew Mujugira, Bosco Bekiita Agaba, Joan Nangendo et autres

The current PrEP delivery models in Uganda do not fully address the socio-economic, cultural, and logistical challenges faced by female sex workers (FSW), resulting in low adherence, mistrust in the healthcare system, and missed opportunities for effective PrEP care, as reflected in …

Ouganda, us, Kenya (code pays fourni par la source)

Correction: Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers

Pauline Mary Amuge, Denis Ndekezi, Moses Mugerwa, Dickson Bbuye et autres

Ouganda, Kenya, us (code pays fourni par la source)

Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers

Pauline Mary Amuge, Denis Ndekezi, Moses Mugerwa, Dickson Bbuye et autres

INTRODUCTION: People living with HIV (PLHIV) have a 20-fold risk of tuberculosis (TB) disease compared to HIV-negative people. In 2021, the uptake of TB preventive treatment among the children and adolescents living with HIV at the Baylor-Uganda HIV clinic was 45%, which …

Ouganda, Kenya, us (code pays fourni par la source)

Chronic immune activation and accelerated immune aging among HIV-infected adults receiving suppressive antiretroviral therapy for at least 12 years in an African cohort

Damalie Nakanjako, Rose Nabatanzi, Isaac Ssinabulya, Lois Bayigga et autres

Background HIV-associated alterations innate and adaptive immune cell compartments are reminiscent of the process of immune aging. Objectives We described immune aging phenotypes among ART-treated HIV-infected adults relative to age-matched HIV-negative counterparts. Methods In a cross-sectional comparative study of HIV-infected adults with …

Ouganda (code pays fourni par la source)

HIV pre-exposure prophylaxis uptake, retention and adherence among female sex workers in sub-Saharan Africa: a systematic review

Ruth Mpirirwe, Ivan Segawa, Kevin Ouma Ojiambo, Onesmus Kamacooko et autres

OBJECTIVE: To evaluate oral pre-exposure prophylaxis (PrEP) uptake, retention and adherence among female sex workers (FSWs) receiving care through community and facility delivery models in sub-Saharan Africa (SSA). DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched online databases (PubMed, MEDLINE, SCOPUS, …

Ouganda (code pays fourni par la source)

COVID-19 vaccine acceptability, and uptake among people living with HIV in Uganda

Richard Muhindo, Stephen Okoboi, Agnes K Kiragga, Rachel Lisa King et autres

BACKGROUND: Despite being a priority population for COVID-19 vaccination, limited data are available regarding acceptability of COVID-19 vaccines among people living with HIV (PLWH) in Sub-Saharan Africa. We described COVID-19 vaccine acceptability and factors associated with vaccine acceptability among PLWH in Uganda. …

Ouganda, us (code pays fourni par la source)

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas Iain Paton, Joseph Musaazi, Cissy M Kityo, Stephen Walimbwa et autres

BACKGROUND: WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to examine whether dolutegravir is non-inferior to darunavir, the best-in-class protease inhibitor drug, and whether maintaining …

sg, gb, Ouganda, Zimbabwe, Kenya (code pays fourni par la source)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Adelline Twimukye, Miriam Laker, Eva Agnes Laker Odongpiny, Florence Ajok et autres

BACKGROUND: In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to describe patient experiences switching from EFV to DTG-based …

Ouganda, gb, us (code pays fourni par la source)

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

Nicholas Iain Paton, Joseph Musaazi, Cissy M Kityo, Stephen Walimbwa et autres

BACKGROUND: The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of …

sg, gb, Ouganda, no, Zimbabwe, Kenya (code pays fourni par la source)

Reasons for first line ART modification over the years during the ART scale up in Uganda

Barbara Castelnuovo, Frank Mubiru, Ivan Kalule, Agnes K Kiragga

BACKGROUND: During the initial scale up of ART in sub-Saharan Africa, prescribed regimens included drugs with high potential for toxicity (particularly stavudine). More recently a growing number of patients requires second line treatment due to treatment failure, especially following the expansion of …

Ouganda (code pays fourni par la source)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga et autres

BACKGROUND: The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients …

Ouganda, gb (code pays fourni par la source)